Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | SHBG | P04278 | 1/20 | 0.64 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | GABRP | O00591 | 2/20 | 0.57 |
| ▸ | GABRD | O14764 | 2/20 | 0.57 |
| ▸ | G6PD | P11413 | 2/20 | 0.57 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.57 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.57 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.57 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.57 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.57 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.57 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25854513 | 0.85 | LMNA (0.69) | LMNAGPBAR1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL6816494 | 0.85 | LMNA (0.69) | LMNAGPBAR1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL7376650 | 0.85 | LMNA (0.69) | LMNAGPBAR1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL15426615 | 0.85 | LMNA (0.69) | LMNAGPBAR1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL6812901 | 0.85 | LMNA (0.69) | LMNAGPBAR1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL8499073 | 0.85 | LMNA (0.69) | LMNAGPBAR1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL6812905 | 0.85 | LMNA (0.69) | LMNAGPBAR1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL19750469 | 0.85 | LMNA (0.69) | LMNAGPBAR1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL23265362 | 0.82 | LMNA (0.64) | LMNAGPBAR1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL22675087 | 0.82 | LMNA (0.64) | LMNAGPBAR1CYP3A4CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10632075-B2 | Glass formulations and uses thereof | RIPPLE THERAPEUTICS CORPORATION (CA) | 2020-04-28 | — | — | US | disclosed |
| US-20190275167-A1 | GLASS FORMULATIONS AND USES THEREOF | RIPPLE THERAPEUTICS CORPORATION (CA) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190275167-A1 | GLASS FORMULATIONS AND USES THEREOF | GBA2, AGER, GBA1 | LMNA 2091/4885GPBAR1 271/4885CYP3A4 854/4885 |
| US-10632075-B2 | Glass formulations and uses thereof | GBA2, AGER, GBA1 | LMNA 2091/4885GPBAR1 271/4885CYP3A4 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.